TP53 and B-cell chronic lymphocytic leukemia: Ibrutinib has demonstrated long-term efficacy in relapsed/refractory (median progression-free survival [PFS] 44.1 months) [1] and frontline (5-year PFS estimate 70%) [2] patient populations with chronic lymphocytic leukemia (CLL), leading a therapeutic renaissance of targeted therapies capable of more frequent durable responses among even high-risk patient populations (4-year PFS among patients with TP53 alterations 79%) [3].